Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1% – Should You Sell?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares were down 3.1% during trading on Monday . The stock traded as low as $0.4687 and last traded at $0.4806. 298,087 shares traded hands during trading, an increase of 56% from the average session volume of 191,271 shares. The stock had previously closed at $0.4958.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, June 24th. Wall Street Zen cut Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Zacks Research raised Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Citius Pharmaceuticals currently has an average rating of “Hold” and an average price target of $5.00.

Citius Pharmaceuticals Stock Performance

The stock’s 50 day simple moving average is $0.59 and its 200-day simple moving average is $0.72. The firm has a market cap of $13.19 million, a price-to-earnings ratio of -0.23 and a beta of 0.98.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.67). On average, analysts expect that Citius Pharmaceuticals, Inc. will post -1.87 EPS for the current fiscal year.

Institutional Trading of Citius Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Citius Pharmaceuticals in the second quarter worth about $32,000. NewEdge Advisors LLC purchased a new stake in Citius Pharmaceuticals in the second quarter valued at approximately $40,000. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals in the 4th quarter worth approximately $46,000. Finally, Heights Capital Management Inc. acquired a new position in Citius Pharmaceuticals in the 4th quarter worth approximately $622,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.